Skip to search formSkip to main contentSkip to account menu

ibritumomab tiuxetan

Known as: ibritumomab tiuxetan [Chemical/Ingredient] 
A monoclonal antibody that is used to treat certain types of B-cell non-Hodgkin lymphoma and is being studied in the treatment and detection of other… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2006
Review
2006
Targeted radiation therapy, or radioimmunotherapy, has been an important recent advancement in the treatment of patients with B… 
Review
2005
Review
2005
AIM Yttrium-90 ((90)Y) ibritumomab tiuxetan (Zevalin) radioimmunotherapy is an effective treatment for relapsed or refractory B… 
2004
2004
90Y ibritumomab tiuxetan is a radioimmunotherapeutic construct that is reported to be an effective treatment for patients with… 
Review
2004
Review
2004
Yttrium 90 ibritumomab tiuxetan consists of the murine monoclonal antibody ibritumomab securely bound to the second-generation… 
2004
2004
UNLABELLED This investigation examined the accuracy of dose calibrator activity measurement of the beta-emitting… 
Review
2004
Review
2004
Targeted radioimmunotherapy, including yttrium 90-labeled ibritumomab tiuxetan (Zevalin) and iodine I 131 tositumomab (Bexxar… 
Review
2003
Review
2003
Radioimmunotherapy (RIT) is a novel treatment modality that combines the benefits of radiotherapy and immunotherapy, enabling… 
Review
2002
Review
2002
The treatment of malignant lymphoma has improved over the past 20 years, but the majority of patients are not cured. New… 
Review
2002
Review
2002
Radioimmunotherapy (RIT) is a new treatment modality for B-cell non-Hodgkin's lymphoma (NHL). Recent clinical trials have clearly…